Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos reports third quarter 2013 financial results
Ustekinumab success in refractory Crohn’s disease
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
The two faces of neuromyelitis optica.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Alemtuzumab for the Treatment of Multiple Sclerosis
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
EMD Serono
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

Pages